SHIRE PLC - Blocklisting - Interim Review
May 23 2017 - 7:10AM
PR Newswire (US)
BLOCK LISTING SIX MONTHLY RETURN
May 23, 2017 - Shire plc
(LSE: SHP, NASDAQ: SHPG)
Name of
applicant: |
Shire plc |
Name of scheme: |
Shire Sharesave
Scheme |
Period of return: |
From: |
November 23, 2016 |
To: |
May 22, 2017 |
Balance of unallotted
securities under scheme(s) from previous return: |
184,611 |
Plus: The
amount by which the block scheme(s) has been increased since the
date of the last return (if any increase has been applied
for): |
Nil |
Less:
Number of securities issued/allotted under scheme(s) during
period (see LR3.5.7G): |
17,079 |
Equals:
Balance under scheme(s) not yet issued/allotted at end of
period: |
167,532 |
|
|
|
|
|
Name of
applicant: |
Shire plc |
Name of scheme: |
Shire Portfolio Share
Plan |
Period of return: |
From: |
November 23, 2016 |
To: |
May 22, 2017 |
Balance of unallotted
securities under scheme(s) from previous return: |
769,615 |
Plus: The
amount by which the block scheme(s) has been increased since the
date of the last return (if any increase has been applied
for): |
Nil |
Less:
Number of securities issued/allotted under scheme(s) during
period (see LR3.5.7G): |
405,083 |
Equals:
Balance under scheme(s) not yet issued/allotted at end of
period: |
364,532 |
|
|
|
|
|
Name of
applicant: |
Shire plc |
Name of scheme: |
Shire Employee Stock
Purchase Plan |
Period of return: |
From: |
November 23, 2016 |
To: |
May 22, 2017 |
Balance of unallotted
securities under scheme(s) from previous return: |
244,057 |
Plus: The
amount by which the block scheme(s) has been increased since the
date of the last return (if any increase has been applied
for): |
Nil |
Less:
Number of securities issued/allotted under scheme(s) during
period (see LR3.5.7G): |
6,359 |
Equals:
Balance under scheme(s) not yet issued/allotted at end of
period: |
237,698 |
|
|
|
|
|
Name of
applicant: |
Shire plc |
Name of scheme: |
Shire Long Term
Incentive Plan 2015 |
Period of return: |
From: |
November 23, 2016 |
To: |
May 22, 2017 |
Balance of unallotted
securities under scheme(s) from previous return: |
2,836,412 |
Plus: The
amount by which the block scheme(s) has been increased since the
date of the last return (if any increase has been applied
for): |
Nil |
Less:
Number of securities issued/allotted under scheme(s) during
period (see LR3.5.7G): |
145,740 |
Equals:
Balance under scheme(s) not yet issued/allotted at end of
period: |
2,690,672 |
|
|
|
|
|
Name of
applicant: |
Shire plc |
Name of scheme: |
Shire Global Employee
Stock Purchase Plan |
Period of return: |
From: |
November 23, 2016 |
To: |
May 22, 2017 |
Balance of unallotted
securities under scheme(s) from previous return: |
1,604,243 |
Plus: The
amount by which the block scheme(s) has been increased since the
date of the last return (if any increase has been applied
for): |
Nil |
Less:
Number of securities issued/allotted under scheme(s) during
period (see LR3.5.7G): |
3,400 |
Equals:
Balance under scheme(s) not yet issued/allotted at end of
period: |
1,600,843 |
|
|
|
|
|
Name of
applicant: |
Shire plc |
Name of scheme: |
Baxalta Exchange
Awards |
Period of return: |
From: |
November 23, 2016 |
To: |
May 22, 2017 |
Balance of unallotted
securities under scheme(s) from previous return: |
20,488,204 |
Plus: The
amount by which the block scheme(s) has been increased since the
date of the last return (if any increase has been applied
for): |
Nil |
Less:
Number of securities issued/allotted under scheme(s) during
period (see LR3.5.7G): |
2,492,337 |
Equals:
Balance under scheme(s) not yet issued/allotted at end of
period: |
17,995,867 |
|
|
|
|
|
Name of contact: |
Sarah Rixon, Company Secretarial
Assistant |
Telephone number of contact: |
01256 894000 |
For further information please
contact:
Investor
Relations |
|
|
Ian Karp |
ikarp@shire.com |
+1 781
482 9018 |
Robert Coates |
rcoates@shire.com |
+44 1256
894874 |
Media |
|
|
Lisa Adler |
lisa.adler@shire.com |
+1-617
588 8607 |
Debbi Ford |
debbi.ford@shire.com |
+1 617 949 9083 |
NOTES TO EDITORS
About Shire
Shire is the leading global biotechnology company focused on
serving people with rare diseases. We strive to develop
best-in-class products, many of which are available in more than
100 countries, across core therapeutic areas including Hematology,
Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders,
Gastrointestinal / Internal Medicine / Endocrine and Hereditary
Angioedema; and a growing franchise in Oncology.
Our employees come to work every day with a shared mission: to
develop and deliver breakthrough therapies for the hundreds of
millions of people in the world affected by rare diseases and other
high-need conditions, and who lack effective therapies to live
their lives to the fullest.
www.shire.com
Copyright y 23 PR Newswire
Shire (LSE:SHP)
Historical Stock Chart
From Apr 2024 to May 2024
Shire (LSE:SHP)
Historical Stock Chart
From May 2023 to May 2024